Dr. Magdalena Skarżyńska from the Institute of Sensory Organs discusses the future of treating hearing loss through pharmacological advancements, gene therapy, and overcoming the physiological barriers of the inner ear.
The Missing Link in Hearing Care
While advanced engineering solutions like hearing aids and implants currently dominate the field, pharmacology may soon become the missing link in comprehensive patient care. Dr. Magdalena Skarżyńska notes that while drug therapy currently plays a secondary role, its future potential is significant.
An Impenetrable Fortress
Delivering medication to the inner ear remains a major challenge due to natural physiological barriers. These protective mechanisms, designed to block toxins, simultaneously prevent therapeutic substances from reaching the target area.
Systemic administration, such as oral or intravenous drugs, often fails because the concentration reaching the inner ear is insufficient. Local delivery methods, similar to drug-eluting stents in cardiology, are now being explored. Cochlear implant electrodes capable of releasing active substances directly into the ear are being developed to reduce inflammation and preserve residual hearing, enhancing overall clinical outcomes.
The High Cost of Life-Saving Treatment
Ototoxic drugs, particularly aminoglycoside antibiotics used in life-threatening infections, can cause permanent hearing loss as a side effect. Experts emphasize that while this is currently a calculated risk, progress is being made.
A protective therapy is already available for pediatric oncology patients receiving cisplatin, which limits the drug’s negative impact. Researchers hope a similar approach will eventually be possible for aminoglycoside antibiotics, allowing for better protection of hearing during essential treatments.
Future Horizons in Gene Therapy
Aging European populations are driving demand for treatments targeting age-related hearing loss, creating a clear opportunity for clinical research. Dr. Magdalena Skarżyńska identifies gene therapies as a key development path.
While widespread implementation of these therapies may take years, early successes in clinical trials are generating significant enthusiasm among biotechnology companies. This discussion took place during the CI 2026 – 18th International Conference on Cochlear Implants and other Implantable Technologies in Warsaw.
